Pursuits
AstraZeneca, E.Digital, ‘Papples’: Intellectual Property
This article is for subscribers only.
April 3 (Bloomberg) -- AstraZeneca Plc, the U.K.’s second-biggest drugmaker, said it may appeal a U.S. court ruling thatinvalidated a patent on its Pulmicort Respules asthma treatmentand cleared the way for generic competition.
The drugmaker “strongly disagrees with” the decision bythe federal court in New Jersey that also said a second patentwasn’t being infringed by producers of a generic version of thetreatment. Actavis Inc., whose generic form of thecorticosteroid has been approved by the U.S. Food and DrugAdministration, said separately that it will begin selling itsversion immediately.